The Effect of Lipid and Inflammatory Profiles on the Morphological Changes of Lipid-Rich Plaques in Patients With Non–ST-Segment Elevated Acute Coronary Syndrome Follow-Up Study by Optical Coherence Tomography and Intravascular Ultrasound by Takarada, Shigeho et al.
T
o
L
E
F
S
T
T
M
W
O
c
m
B
p
M
i
r
i
m
R
(
s
s
H
r
(
p
C
w
C
b
©
F
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 7 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 0 . 0 5 . 0 0 1he Effect of Lipid and Inflammatory Profiles
n the Morphological Changes of
ipid-Rich Plaques in Patients With Non–ST-Segment
levated Acute Coronary Syndrome
ollow-Up Study by Optical Coherence Tomography and Intravascular Ultrasound
higeho Takarada, MD, PHD, Toshio Imanishi, MD, PHD, Kohei Ishibashi, MD,
akashi Tanimoto, MD, Kenichi Komukai, MD, Yasushi Ino, MD, Hironori Kitabata, MD,
akashi Kubo, MD, PHD, Atsushi Tanaka, MD, PHD, Keizo Kimura, MD, PHD,
asato Mizukoshi, MD, PHD, Takashi Akasaka, MD, PHD
akayama, Japan
bjectives The aim of this study was to determine the relationship between the morphological
hanges of nonculprit lipid-rich plaques and several clinical proﬁles in patients with non–ST-seg-
ent elevated acute coronary syndrome (NSTEACS).
ackground Identiﬁcation of coronary lesion with morphological characteristics of rupture-prone
laques is still difﬁcult.
ethods Eighty-two consecutive patients with NSTEACS who underwent percutaneous coronary
ntervention were enrolled. The changes in total atheroma volume (TAV) of residual nonculprit lipid-
ich plaques and the changes in the corresponding ﬁbrous cap thickness (FCT) were assessed by
ntravascular ultrasound and optical coherence tomography, respectively, at baseline and after 9
onths.
esults The percentage changes in TAV (mm3) of lipid-rich plaques and in the corresponding FCT
m) over the 9-month follow-up period were 3.1  11% and 15  17%, respectively. There was no
igniﬁcant correlation between the changes in TAV and those in FCT. The change in TAV showed a
igniﬁcant correlation with reduction of the low-density lipoprotein/high-density lipoprotein (LDL/
DL) ratio (r  0.42, p  0.01). In contrast, the change in FCT showed no correlation with LDL/HDL
atio but had a signiﬁcant positive correlation with changes in high-sensitivity C-reactive protein
r  0.44, p  0.01). Furthermore, in multivariate logistic analysis, statin use was an independent
redictor of changes in well-stabilized plaques that showed both TAV reduction and FCT increase.
onclusions The changes in TAV and FCT of coronary plaques over a 9-month observation period
ere related to 2 different independent factors (i.e., reduction of LDL-cholesterol and high-sensitivity
-reactive protein, respectively). Furthermore, lipid-lowering therapy with statin has the potential to sta-
ilize these parameters by both plaque reduction and FCT. (J Am Coll Cardiol Intv 2010;3:766–72)
2010 by the American College of Cardiology Foundation
rom the Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.anuscript received December 10, 2009; revised manuscript received April 26, 2010, accepted May 1, 2010.
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767he vulnerability of coronary plaques has been implicated in
he pathogenesis of acute coronary syndrome. Plaques prone to
upture are characterized by a large necrotic core and a thin
brous cap with macrophage infiltration into the cap (1,2). In
he clinical setting, monitoring atheroma volume changes with
erial intravascular ultrasound (IVUS) has been used to char-
cterize the natural history of atherosclerosis and the effects of
ntiatherosclerotic therapeutic strategies (3–5).
Recently, intravascular optical coherence tomography
OCT) has been proposed as a high-resolution imaging
ethod for plaque characterization. Optical coherence tomog-
aphy might allow us to evaluate the micro structural charac-
eristics of coronary plaques, including the fibrous cap thick-
ess (FCT) in vitro and in vivo (6). The OCT and
orresponding histological findings in postmortem studies
howed good correlations regarding FCT, which is thought to
e a major factor in the assessment of plaque vulnerability as
ell as the atherosclerotic plaque burden (7).
Analysis of lipid-rich plaques with both OCT and IVUS
ndicated that large lipid-rich plaques are not always sealed
ith a thin fibrous cap. Statin is believed to contribute to
econdary prevention of cardiovascular events by reducing
ow-density lipoprotein (LDL) levels followed by regression of
ipid-rich plaque. In addition, statin has been reported to
ignificantly reduce the incidence of major cardiovascular
vents, even in subjects with normal cholesterol levels, with
levated high-sensitivity C-reactive protein (hs-CRP) (8).
herefore, we hypothesized that lipid profile and hs-CRP
eflect different mechanisms of stabilization of vulnerable
laques.
In this study, the 9-month serial change of mild to
oderate coronary atheroma was analyzed in patients
ith non–ST-segment elevated acute coronary syndrome
NSTEACS) with serial IVUS and OCT. We compared
hanges in total atheroma volume (TAV) and FCT of the
laques, both of which are thought to be the major factors
nfluencing plaque vulnerability, in relation to hs-CRP and
erum lipids. Furthermore, we also examined which factors
ave the potential to stabilize lipid-rich plaques.
ethods
tudy population. The study population was drawn from 160
onsecutive NSTEACS patients admitted to Wakayama
edical University Hospital between January 2006 and
ovember 2007. Subjects who had significant left main
oronary artery disease (n 3), congestive heart failure (n
), renal insufficiency with baseline serum creatinine 1.5
g/dl (n  8), or previous or current use of lipid-lowering
herapy (n  12) were excluded. The IVUS and OCT
tudies of entire culprit vessels were performed in a residual
10 patients with NSTEACS. Of 110 patients, 82 who
ave consent to undergo follow-up study by both IVUS and
CT were enrolled in this study. alinical and biochemical parameters. Blood samples were
ollected at baseline (at the day of discharge) and at the
nd of the 9-month follow-up period from all subjects.
he criteria for several coronary risk factors at baseline
ere defined as follows: hypertension: blood pressure
140/90 mm Hg or a history antihypertensive drug
rescription; diabetes mellitus: fasting plasma glucose
126 mg/dl, and casual plasma glucose 200 mg/dl; and
yperlipidemia: total cholesterol level 220 mg/dl or
riglyceride 150 mg/dl. Percentage change of each
arameters (LDL, HDL, LDL/HDL, hs-CRP) was
alculated as: (follow-up  baseline)/baseline.
This protocol was approved by the Wakayama Medical
niversity Ethics Committee, and all patients provided
nformed consent before initial coronary angiography.
aseline catheterization. Oral
spirin (162 mg) and intrave-
ous heparin (100 U/kg) were
dministered before percutane-
us coronary intervention (PCI).
ardiac catheterization was per-
ormed via the femoral approach
ith a 6-F sheath and catheters.
he culprit lesion was identified
n the basis of coronary angiog-
aphy findings as well as those of
lectrocardiography and echo-
ardiography. After PCI for the
ulprit lesion of acute coronary
yndromes, IVUS and OCT ex-
minations of the target vessels
ere performed entirely. The
arget plaques in this study were
ipid-rich plaques with a fibrous
ap of various thickness, which
ere angiographically mild or
oderate lesions (30% to 70%
tenosis) located 10 mm from
he culprit site of NSTEACS.
hen more than 2 plaques were recognized in 1 vessel,
hose with the thinnest fibrous cap were selected as target
laques in this study. After a 9-month follow-up period,
VUS and OCT examinations were performed after coro-
ary angiography. The operator placed each IVUS and
CT catheter in the vessel originally investigated and
ositioned it distal to the target plaque, which was carefully
dentified on the basis of the distance from the reproducible
andmarks such as major branches, spotty calcification, side
ein, and stent edge.
An automatic pullback was repeated under conditions
dentical to those in the baseline study. Interobserver and
ntraobserver variabilities of IVUS and OCT analyses were
Abbreviations
and Acronyms
CI  confidence interval
FCT  fibrous-cap thickness
HDL  high-density
lipoprotein
hs-CRP  high-sensitivity
C-reactive protein
IVUS  intravascular
ultrasound
LDL  low-density
lipoprotein
NSTEACS  non–ST-segment
elevated acute coronary
syndrome
OCT  optical coherence
tomography
OR  odds ratio
PCI  percutaneous
coronary intervention
TAV  total atheroma
volumessessed by the evaluation of all images by 2 independent
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768nvestigators and by the same reader at 2 separate time
oints, respectively.
CT examination and analysis. Intravascular OCT imaging
as performed according to the previous description (6).
riefly, after administration of 100 to 300 g of intracoro-
ary nitroglycerin, a 0.016-inch OCT catheter (ImageWire,
ightLab Imaging, Inc., Westford, Massachusetts) was
dvanced through a 3-F occlusion balloon catheter to the
istal site of the culprit branch.
The OCT images were analyzed with proprietary offline
oftware provided by LightLab Imaging, Inc. The targets
ere initially defined as lipid-rich plaques, which were
bserved as plaques with lipid in 2 or more quadrants (9,10)
nd with a recognizable image of a fibrous cap on OCT
nalysis. The FCT of each lipid-rich plaque was defined as
he minimum distance from the coronary artery lumen to
he inner border of the necrotic core.
VUS examination and analysis. After re-administration of
00 to 300 g of intracoronary nitroglycerin, a 2.9-F
0-MHz IVUS catheter (Eagle-Eye, Volcano Therapeutics,
nc., Rancho Cordova, California) was inserted 10 mm
istal to the target plaque decided by OCT examination and
ubsequently pulled back with a motorized pullback system
t a rate of 0.5 mm/s. It was confirmed that the target plaque
as identical to that for which FCT was measured by OCT.
he TAV was calculated as:  (EEMCSA  LUMENCSA),
here EEMCSA is the external elastic membrane cross-
ectional area and LUMENCSA is the luminal cross sec-
ional area in the most diseased 10-mm segment with the
argest plaque at each baseline and follow-up period. The
ercentage change in TAV was defined as: (follow-up –
aseline TAV)/baseline TAV.
tatistical analysis. Statistical analysis was performed with
tatView, version 5.0.1 (SAS Institute, Cary, North Caro-
ina). Continuous variables are shown as mean  SD.
omparison between baseline and follow-up was performed
ith the paired t test. Correlation between continuous
ariables was estimated with Pearson correlation coefficient.
value of p  0.05 was considered statistically significant.
multivariate logistic analysis was used to determine the
ignificant factors indicating the “well-stabilized plaque.”
fter univariate screening, any candidate variables with a
alue of p  0.10 were entered into a multivariate model
hat then identified independent predictors of outcome
efined by a multivariate value of p  0.05.
esults
linical characteristics. A total of 82 plaques (82 patients)
ere evaluated with OCT and IVUS at baseline and at
-month follow-up. Patients with NSTEACS were treated
ith antithrombotic therapy and underwent PCI within
8 h of admission. Baseline clinical characteristics and
oncomitant medical therapy during the 9-month follow-up 0eriod are also listed in Table 1. The mean LDL/HDL
atio was 2.6  0.8, and 58 patients (71%) received statins
uring the follow-up period.
hanges in plaque morphology. There were no procedure-
elated complications associated with the use of IVUS or
CT.
Figure 1 shows representative IVUS and OCT images
btained at the same position near a major side branch in
STEACS patients with statin treatment during the
-month follow-up period. Slight regression of plaque
urden was observed by IVUS from 63.4 mm3 at baseline to
0.4 mm3 at the 9-month follow-up. Furthermore, OCT
evealed a significant increase in FCT at 9 months (310 m)
n comparison with the baseline value (90 m).
The serial changes in plaque burden assessed by IVUS and
hanges in FCT assessed by OCT are shown in Table 2. The
AV did not change significantly (74 44 mm3 to 76 45
m3, p NS) during the 9-month follow-up, although the
CT increased significantly (95  32 m to 112  45 m,
 0.05).
orrelation between plaque morphology and laboratory
utcomes. Figure 2 shows that there was no significant
orrelation between the change in TAV assessed by IVUS
nd the change in FCT assessed by OCT (r  0.14, p 
.62). The change in TAV was significantly correlated with
he change in LDL/HDL ratio (r  0.42, p  0.01),
lthough no correlation was observed with change in hs-
RP (r  0.22, p  0.06). In contrast, change in FCT was
ignificantly correlated with the change in hs-CRP (r 
Table 1. Baseline Characteristics of 82 Patients
Age, yrs 66 14
Male 62 (76)
Cardiovascular factors
Prior CAD 8 (10)
Hypertension 61 (76)
Diabetes 18 (23)
Dyslipidemia 62 (75)
Smoker 22 (28)
Culprit vessel
LAD 50 (61)
LCX 10 (12)
RCA 22 (27)
Therapy during 9 months
Aspirin 82 (100)
ACE inhibitor or ARB 73 (89)
Beta blocker 74 (90)
Statin 58 (71)
Nitrates 25 (30)
Values are n (%) or mean SD.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; CAD coronary
arterydisease; LAD left anterior descendingcoronary artery; LCX left circumflexartery; RCA
right coronary artery..44, p  0.01) but not with that in LDL/HDL ratio (r 
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769.08, p  0.31) (Fig. 3). Meanwhile, absolute values (LDL,
DL, hs-CRP) at both baseline and follow-up could not
ave any association with the change in plaque morphology
data not shown).
redictors of well-stabilized plaques. Plaques with both a
ecrease in TAV and increase in FCT at the 9-month
ollow-up were defined as well-stabilized plaques, and the
resent study included 31 such plaques (39%). The results of
nivariate logistic regression analysis indicated that hyper-
ension (odds ratio [OR]: 0.43; 95% confidence interval
CI]: 0.17 to 1.1, p  0.075) and diabetes mellitus (OR:
.36; 95% CI: 0.14 to 0.97, p  0.042) were negative
redictive factors and statin use during the 9-month
ollow-up period (OR: 4.6; 95% CI: 1.7 to 13, p  0.0033)
Figure 1. Representative Case of Well-Stabilized Plaques
The left 3 panels illustrate the appearance of the same cross-section with intr
right 3 panels show the same cross-section after 9-month follow-up periods.
ﬁbrous cap was increased from 90 to 310 m; arrows delineate the ﬁbrous ca
Table 2. Lipid, Inflammatory Marker, and Morphologi
Follow-Up Period
Baseline
LDL (mg/dl) 122 38
HDL (mg/dl) 44 10
LDL/HDL 2.6 0.8
hs-CRP (mg/dl) 0.72 2.64
Total atheroma volume (mm3) 74 44
Fibrous cap thickness (m) 95 32
Values presented as mean SD unless otherwise indicated.HDL high-density lipoprotein; hs-CRP high-sensitivity C-reactive proteas a positive predictor of “well-stabilized plaque.” Multi-
ariate logistic regression analysis demonstrated that statin-
se (OR: 3.5; 95% CI: 1.1 to 11, p  0.032) was an
ndependent predictive factor of “well-stabilized plaque.”
iscussion
n the present study, we investigated the morphological
actors involved in stabilizing lipid-rich plaque. The results
resented here indicate that the changes in FCT and
ipid-rich plaque volume were determined by different
actors (i.e., changes in hs-CRP and in LDL/HDL, respec-
ively). Furthermore, administration of statin was confirmed
o be a suitable form of therapy to stabilize vulnerable
lar ultrasound and optical coherence tomography at baseline, whereas the
ma volume was reduced from 63.2 mm3 to 60.9 mm3, and the thickness of
ofile Compared at Baseline and After 9-Month
llow-Up Percentage Change p Value
3 21 16 4 0.010
5 11 2.0 0.8 0.087
.1 0.8 12 20 0.032
0 2.52 16 24 0.010
6 45 3.1 11 0.120
2 45 15 17 0.001avascu
Atherocal Pr
Fo
10
4
2
0.6
7
11in; LDL low-density lipoprotein.
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770ipid-rich plaques in terms of morphological assessment
Table 3).
There has been a great deal of research interest regarding
he relationships among lipids, inflammation, and their
ffects on the arterial wall (11). Intravascular ultrasound has
een used clinically as a representative imaging modality to
valuate the coronary arterial wall and plaque morphology,
ncluding quantification of plaque burden, but it is not
ossible to determine the thickness of the cap with this
ethod, due to its poor resolution. In contrast, the high
esolution of OCT makes it an ideal imaging modality for
icrostructural evaluation, such as determination of FCT
12,13), although this method is not suitable for evaluation
f plaque burden due to its poor penetration depth. There-
ore, assessment with a combination of both IVUS and
CT has the potential to allow detailed assessment of
hanges in plaque morphology.
The pathological features of the most common form of
ulnerable plaque include a large lipid pool within the
laque, a thin fibrous cap, and macrophage accumulation
ithin the cap, resulting in the expression of a proteolytic
nzyme that weakens the fibrous cap and ultimately pro-
otes plaque disruption (14). The ideal changes from
ulnerable to stable plaque are an increase in FCT and a
ecrease in TAV. Pathological studies have also shown that
uptured plaques contain a large lipid core underlying a thin
brous cap poor in smooth muscle cells and collagen (15).
specially, collagen is believed to be the main component of
Figure 2. Correlation Between Percentage Change of FCT and TAV
The change in total atheroma volume (TAV) assessed by intravascular ultra-
sound and the change in ﬁbrous cap thickness (FCT) assessed by optical
coherence tomography had no correlation with each other (r  0.14,
p  0.62).he fibrous cap responsible for its tensile strength (16). One cf the main factors responsible for triggering of most acute
oronary events seems to be the balance between collagen
roduction and degradation (17).
Nabata et al. (18) reported that CRP directly mediates
roduction of matrix metalloproteinase-9, which destroys
ollagen through induction of tumor necrosis factor-alpha
nd interleukin-1-beta in vitro, suggesting an active role of
RP in destabilization of the fibrous cap leading to pro-
ression of plaque rupture.
The results of the present study indicated that changes in
CT are not correlated with changes in LDL-C but with
hanges in hs-CRP, which is consistent with the in vitro
esults of Nabata et al. (18). In contrast, Nissen et al. (3)
roposed that the decrease in CRP level was independently
nd significantly correlated with plaque progression after
djustment for reduction of these lipid levels. Although this
id not agree with our observations, the whole population in
heir study received moderate or intensive statin treatment,
n contrast to the rate of 71% of patients in the present
tudy. The relationship between changes in CRP and TAV
bserved in the REVERSAL (REVERSing Atherosclerosis
ith Aggressive Lipid Lowering) study was not found when
he data were combined with those of the ACTIVATE
ACAT IntraVascular Atherosclerosis Treatment Evalua-
ion) study, in which statin therapy was not an active
xperimental therapy (19).
In the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
valuation and Infection Therapy–Thrombolysis In Myo-
ardial Infarction 22) study of 3,745 patients with acute
oronary syndromes, Ridker et al. (20) reported that those
ith LDL-C 70 mg/dl or CRP 2 mg/l after statin
herapy had a lower rate of recurrent coronary events,
ompared with those with LDL-C or CRP that remained
igher than these levels. Furthermore, rosuvastatin signifi-
antly reduced the incidence of major cardiovascular events
ven in healthy subjects without hyperlipidemia but with
levated hs-CRP (21). In the present study, we found that
tatin therapy was an independent predictive factor of
laques that have caused both plaque reduction and fibrous
ap thickening involved in stabilizing lipid-rich plaque.
herefore, it is reasonable to assume that the results of the
resent study might be relevant to the mechanism by which
tatin therapy reduces the rate of recurrent coronary events
ven in patients without hyperlipidemia.
tudy limitations. First, the study population was relatively
mall, and the possibility of selection bias cannot be ex-
luded, although consecutive subjects who were eligible and
onsented to participate in the study were selected. High-
isk patients, such as those with cardiogenic shock and fatal
rrhythmia, were excluded, because the observations with
CT required balloon occlusion of the coronary flow and
ushing with lactated Ringer’s solution to avoid red blood
ell interference to allow visualization of the vessel wall.
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771urthermore, we assessed the change of only 1 plaque
orphology in a culprit vessel in this study, because it
equires repeated balloon occlusion and much greater
mount of lactate Ringer’s solution for the assessment of the
ultiple plaques in 3-vessel coronary trees. In the near
uture, a new-generation OCT system (frequency-domain
CT), which needs no occlusion balloon and less flush with
ts faster pullback speed, will be expected to assess the
atural course of all coronary plaques in entire coronary
rees.
Figure 3. The Correlation Between the Lipid Profile and Percentage Chang
Scatter plots of (A) % total atheroma volume (TAV) to % low-density lipopr
(C) % ﬁbrous-cap thickness (FCT) to %LDL/HDL, and (D) %FCT to %CRP. Pearso
Table 3. Univariate and Multivariate Logistic Regression Analyses as Predi
Univariate Analysis
OR (95% CI)
Age, yrs 0.98 (0.93–1.04)
Sex 1.6 (0.46–5.4)
Hyperlipidemia 0.91 (0.33–2.5)
Hypertension 0.43 (0.17–1.1)
Diabetes mellitus 0.36 (0.14–0.97)
Statin 4.6 (1.7–13.0)
The plaques that both the total atheroma volume decreased and the fibrous cap thickness increaseCI confidence interval; OR odds ratio.Second, this study was a cross-sectional study and thus
ould not assess the question of whether the change of
laque morphology holds great significance in clinical set-
ings. Future longitudinal and prospective studies are
eeded to determine whether the change of plaque mor-
hology is relevant to the risk of future cardiovascular events
n our subjects.
Third, the percentage of subjects who were prescribed
tatins in this study was 71%, which might be small compared
ith prescription rates worldwide. In Japan, the prescribed
CT and TAV
high-density lipoprotein (LDL/HDL), (B) %TAV to % C-reactive protein (CRP),
rrelation coefﬁcient (r) and the p value are depicted in the insert.
of Well-Stabilized Plaques
lue
Multivariate Analysis
OR (95% CI) p Value
— —
— —
— —
5 0.58 (0.21–1.6) 0.300
2 0.68 (0.22–2.1) 0.500
33 3.5 (1.1–11.0) 0.032
defined as a “well-stabilized plaque.”e of F
otein/ctors
p Va
0.60
0.47
0.86
0.07
0.04
0.00
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772nitiation of statins was recommended for patients whose
DL-cholesterol was below 100 mg/dl according to the
uidelines published by the Japan Atherosclerosis Society (22).
Lastly, we used only the hs-CRP level in the peripheral
lood as the main proinflammatory biomarker, although
ther biomarkers such as interleukin-6 and lipoprotein-
ssociated phospholipase A2 might affect plaque
orphology.
onclusions
he changes in atheroma volume and FCT were related to
ifferent independent factors involved in stabilizing lipid-
ich plaques (i.e., changes in LDL/HDL and hs-CRP,
espectively). Furthermore, statin treatment seems to be a
uitable form of therapy for stabilizing vulnerable plaques by
oth decreasing the amount of lipid-rich plaque and in-
reasing the FCT.
eprint requests and correspondence: Dr. Takashi Akasaka,
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